{
  "metadata": {
    "case_id": 78,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T18:38:28.900945",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/78_NCT04568031.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/78_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.42,
          0.11
        ],
        [
          0.18,
          0.58
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.42,
          "status": "matched",
          "ref_item": {
            "label": "Part I",
            "type": "ACTIVE_COMPARATOR",
            "description": "Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.",
            "interventionNames": [
              "Drug: AZD1222"
            ]
          },
          "pred_item": {
            "label": "AZD1222",
            "type": "EXPERIMENTAL",
            "description": "Participants received two doses of AZD1222 (ChAdOx1 nCoV-19), 5 × 10^10 viral particles per dose, administered as intramuscular injections into the deltoid muscle on Days 1 and 29.",
            "interventionNames": [
              "AZD1222 (ChAdOx1 nCoV-19)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.58,
          "status": "matched",
          "ref_item": {
            "label": "Part II",
            "type": "PLACEBO_COMPARATOR",
            "description": "Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.",
            "interventionNames": [
              "Drug: 0.9% (w/v) saline"
            ]
          },
          "pred_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants received two doses of placebo (0.9% saline), administered as intramuscular injections into the deltoid muscle on Days 1 and 29.",
            "interventionNames": [
              "Placebo (saline 0.9%)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.94,
          0.1
        ],
        [
          0.12,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "AZD1222",
            "description": "For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2",
            "armGroupLabels": [
              "Part I"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "AZD1222 (ChAdOx1 nCoV-19)",
            "description": "AZD1222 is a replication-deficient simian adenovirus-vectored COVID-19 vaccine encoding the full-length SARS-CoV-2 spike protein. In this study it was manufactured according to Good Manufacturing Practice and given as two intramuscular injections of 5 × 10^10 viral particles per dose into the deltoid muscle on Days 1 and 29.",
            "armGroupLabels": [
              "AZD1222"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "0.9% (w/v) saline",
            "description": "For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.",
            "armGroupLabels": [
              "Part II"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo (saline 0.9%)",
            "description": "Placebo comparator consisting of 0.9% weight/volume saline solution, administered as two intramuscular injections into the deltoid muscle on Days 1 and 29, matching the AZD1222 dosing schedule.",
            "armGroupLabels": [
              "Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.97,
          0.05
        ],
        [
          0.1,
          0.84
        ],
        [
          0.08,
          0.8
        ],
        [
          0.05,
          0.88
        ],
        [
          0.08,
          0.73
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay",
            "description": "Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is \\>= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level. The percentage of participants with a post-vaccination seroresponse (\\>= 4-fold rise in titers from Day 1 baseline value to Day 57) to the S antigen of AZD1222 as measured by MSD serology assay is reported.",
            "timeFrame": "Baseline (Day 1) and Day 57"
          },
          "pred_item": {
            "measure": "Anti-SARS-CoV-2 spike seroresponse rate",
            "description": "Proportion of participants with a seroresponse to the SARS-CoV-2 spike antigen, defined as a ≥4-fold rise in antibody titre from the Day 1 baseline value following vaccination with AZD1222.",
            "timeFrame": "Day 57 after first vaccination (28 days after the second dose)"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Local Solicited Adverse Events (AE)",
            "description": "Solicited AEs are local or systemic predefined AEs for reactogenicity assessment. Participants were given an axillary thermometer, tape measure, and access to app for the solicited AE eDiary, with instructions on use, along with the emergency 24-hour telephone number to contact the on-call study physician if needed. Participants were instructed to record for 7 days following administration of each dose of AZD1222, the timing and severity of local and systemic solicited AEs, if applicable, and whether medication was taken to relieve the symptoms.",
            "timeFrame": "From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Systemic Solicited AEs",
            "description": "Solicited AEs are local or systemic predefined AEs for reactogenicity assessment. Participants were given an axillary thermometer, tape measure, and access to app for the solicited AE eDiary, with instructions on use, along with the emergency 24-hour telephone number to contact the on-call study physician if needed. Participants were instructed to record for 7 days following administration of each dose of AZD1222, the timing and severity of local and systemic solicited AEs, if applicable, and whether medication was taken to relieve the symptoms.",
            "timeFrame": "From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": 1,
          "score": 0.88,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With AEs, Serious AEs (SAE) and Adverse Event of Special Interest (AESI) Occurring Post Each Dose of Study Vaccination",
            "description": "An AE is the development of any untoward medical occurrence in a clinical study participant administered medicinal product and which does not necessarily have a causal relationship with this medicinal product. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is an AE occurring during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening; in-participant hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital abnormality or birth defect; an important medical event. The AESIs were events of scientific and medical interest specific to the further understanding of the study vaccination safety profile and required close monitoring and rapid communication by the investigators to the sponsor.",
            "timeFrame": "From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days"
          },
          "pred_item": {
            "measure": "Solicited local and systemic reactogenicity and adverse events",
            "description": "Occurrence of solicited local (pain, tenderness, redness, swelling, induration at the injection site) and systemic (fever, chills, muscle pain, fatigue, headache, malaise, nausea, vomiting) reactogenicity signs/symptoms in the 6 days after each dose; occurrence of unsolicited adverse events, serious adverse events (SAEs), and adverse events of special interest (AESIs) for 28 days after each dose; and change from baseline in safety laboratory measures (haematology and clinical chemistry).",
            "timeFrame": "Solicited reactogenicity: Days 1–7 and Days 29–35 after each dose; unsolicited AEs, SAEs, AESIs, and lab changes: Days 1–29 and Days 29–57 after each dose"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters",
            "description": "Clinical laboratory values were evaluated for each laboratory parameter as applicable including hematology and clinical chemistry. The baseline was defined as the last non-missing measurement taken prior to the first dose of study vaccination (including unscheduled measurements, if any).",
            "timeFrame": "From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 7,
      "pred_count": 6,
      "similarity_matrix": [
        [
          0.97,
          0.78,
          0.72,
          0.86,
          0.72,
          0.1
        ],
        [
          0.8,
          0.68,
          0.96,
          0.94,
          0.78,
          0.05
        ],
        [
          0.78,
          0.6,
          0.9,
          0.93,
          0.78,
          0.08
        ],
        [
          0.86,
          0.97,
          0.72,
          0.74,
          0.82,
          0.08
        ],
        [
          0.4,
          0.7,
          0.83,
          0.78,
          0.93,
          0.03
        ],
        [
          0.68,
          0.7,
          0.78,
          0.88,
          0.93,
          0.05
        ],
        [
          0.05,
          0.08,
          0.05,
          0.05,
          0.07,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With Seroresponse to the Receptor-Binding Domain (RBD) Antigen of AZD1222 as Measured by MSD Serology Assay",
            "description": "Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is \\>= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level. The percentage of participants with a post-vaccination seroresponse (\\>= 4-fold rise in titers from Day 1 baseline value to Day 57) to the RBD antigen of AZD1222 as measured by MSD serology assay is reported.",
            "timeFrame": "Baseline (Day 1) and Day 57"
          },
          "pred_item": {
            "measure": "Anti-SARS-CoV-2 receptor-binding domain seroresponse rate",
            "description": "Proportion of participants with a seroresponse for the SARS-CoV-2 receptor-binding domain (RBD) antigen, defined as a ≥4-fold rise in antibody titre from the Day 1 baseline value following vaccination with AZD1222.",
            "timeFrame": "Day 57 after first vaccination (28 days after the second dose), with additional serology time points up to Day 365"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Geometric Mean Titers (GMTs) for SARS-CoV-2 S and RBD Antibodies as Measured by MSD Serology Assay",
            "description": "The GMT was calculated as the antilogarithm of Σ(log base 2 transformed titer/n), i.e. as the anti-logarithm transformation of the mean of the log-transformed titer, where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365"
          },
          "pred_item": {
            "measure": "Geometric mean titres (GMTs) and geometric mean fold rise of anti-spike antibodies",
            "description": "Geometric mean titres and geometric mean fold rise of antibodies against the SARS-CoV-2 spike antigen measured by validated multiplex electrochemiluminescent immunoassay.",
            "timeFrame": "At each serology time point up to Day 365 (Days 1, 15, 29, 43, 57 and planned later visits)"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 3,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 S and RBD Antibodies as Measured by MSD Serology Assay",
            "description": "The fold rise was calculated as the ratio of the post-vaccination titer level to the baseline titer level, where baseline was defined as the last measurement taken before the first dose of study vaccination. The GMFR was calculated as anti-logarithm of Σ (log base 2 transformed (post-vaccination titer/ pre-vaccination titer)/n). Where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365"
          },
          "pred_item": {
            "measure": "Geometric mean titres (GMTs) and geometric mean fold rise of anti-RBD antibodies",
            "description": "Geometric mean titres and geometric mean fold rise of antibodies against the SARS-CoV-2 receptor-binding domain measured by validated multiplex electrochemiluminescent immunoassay.",
            "timeFrame": "At each serology time point up to Day 365 (Days 1, 15, 29, 43, 57 and planned later visits)"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 1,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With Seroresponse to SARS-CoV-2 Neutralizing Antibodies (nAb) of AZD1222 as Measured by Pseudo-Neutralization Assay",
            "description": "Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is \\>= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level. The percentage of participants with a post-vaccination seroresponse (\\>= 4-fold rise in titers from Day 1 baseline value to Day 57) to SARS-CoV-2 nAb of AZD1222 as measured by pseudo-neutralization assay is reported.",
            "timeFrame": "Baseline (Day 1) and Day 57"
          },
          "pred_item": {
            "measure": "Neutralizing antibody seroresponse rate",
            "description": "Proportion of participants with a seroresponse in SARS-CoV-2 neutralizing antibodies as measured by a pseudo-virus neutralization assay.",
            "timeFrame": "Day 57 after first vaccination (28 days after the second dose), with sampling at Days 1, 29, and 57 and planned follow-up up to Day 365"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "GMTs for SARS-CoV-2 nAb as Measured by Pseudo-Neutralization Assay",
            "description": "The GMT was calculated as the antilogarithm of Σ(log base 2 transformed titer/n), i.e. as the anti-logarithm transformation of the mean of the log-transformed titer, where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 29, 57, 183, and 365"
          },
          "pred_item": null
        },
        {
          "ref_idx": 5,
          "pred_idx": 4,
          "score": 0.93,
          "status": "matched",
          "ref_item": {
            "measure": "GMFR for SARS-CoV-2 nAb as Measured by Pseudo-Neutralization Assay",
            "description": "The fold rise was calculated as the ratio of the post-vaccination titer level to the baseline titer level, where baseline was defined as the last measurement taken before the first dose of study vaccination. The GMFR was calculated as anti-logarithm of Σ (log base 2 transformed (post-vaccination titer/ pre-vaccination titer)/n). Where 'n' is the number of participants with titer information.",
            "timeFrame": "Baseline (Day 1) and Days 29, 57, 183, and 365"
          },
          "pred_item": {
            "measure": "Geometric mean titres (GMTs) and geometric mean fold rise of SARS-CoV-2 neutralizing antibodies",
            "description": "Geometric mean titres and geometric mean fold rise of SARS-CoV-2 neutralizing antibodies measured by HIV-1-based pseudo-virus neutralization assay.",
            "timeFrame": "At each neutralizing antibody time point up to Day 365 (Days 1, 29, 57 and planned later visits)"
          }
        },
        {
          "ref_idx": 6,
          "pred_idx": 5,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With SAEs and AESIs Occurring Throughout the Study",
            "description": "An SAE is an AE occurring during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening; in-participant hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital abnormality or birth defect; an important medical event. The AESIs were events of scientific and medical interest specific to the further understanding of the study vaccination safety profile and required close monitoring and rapid communication by the investigators to the sponsor.",
            "timeFrame": "From Day 1 up to final DCO of 17 January 2022, up to a maximum of 365 days"
          },
          "pred_item": {
            "measure": "Occurrence of serious adverse events and adverse events of special interest (long-term)",
            "description": "Number and proportion of participants with SAEs and AESIs, including events such as anaphylactic reactions, immune-mediated neurologic disorders, and thrombosis with thrombocytopenia syndrome as monitored during the study.",
            "timeFrame": "From first vaccination through Day 365 after the first dose"
          }
        }
      ]
    }
  ]
}